You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDapoxetine
Accession NumberDB04884
TypeSmall Molecule
GroupsInvestigational
Description

Dapoxetine is a selective serotonin reuptake inhibitor, for the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo. Alza submitted a NDA to the FDA for dapoxetine for the treatment of premature ejaculation in December 2004. In October 2005, the company received a FDA Non-Approvable letter from the FDA, at which time they planned to work with regulators to address outstanding questions.

Structure
Thumb
Synonyms
Dapoxetina
Dapoxetinum
External Identifiers
  • LY 210448
Approved Prescription ProductsNot Available
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIGB2433A4M3
CAS number119356-77-3
WeightAverage: 305.4134
Monoisotopic: 305.177964363
Chemical FormulaC21H23NO
InChI KeyInChIKey=USRHYDPUVLEVMC-FQEVSTJZSA-N
InChI
InChI=1S/C21H23NO/c1-22(2)20(18-10-4-3-5-11-18)15-16-23-21-14-8-12-17-9-6-7-13-19(17)21/h3-14,20H,15-16H2,1-2H3/t20-/m0/s1
IUPAC Name
dimethyl[(1S)-3-(naphthalen-1-yloxy)-1-phenylpropyl]amine
SMILES
CN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
KingdomOrganic compounds
Super ClassBenzenoids
ClassNaphthalenes
Sub ClassNot Available
Direct ParentNaphthalenes
Alternative Parents
Substituents
  • Phenylpropylamine
  • Naphthalene
  • Aralkylamine
  • Alkyl aryl ether
  • Monocyclic benzene moiety
  • Tertiary aliphatic amine
  • Tertiary amine
  • Ether
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homopolycyclic compound
Molecular FrameworkAromatic homopolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the treatment of premature ejaculation.
PharmacodynamicsDapoxetine is a selective serotonin reuptake inhibitor currently undergoing trials through Alza (under license from GenuPro, a collaboration between Eli Lilly and PPD). Dapoxetine is a short-acting SSRI drug currently being considered for approval by the Food and Drug Administration (FDA) for the treatment of premature ejaculation in men, which would make it the first drug approved for such treatment. Despite two clinical trials finished in 2006, experts doubt it will be approved by the FDA soon because SSRIs come with undesirable side-effects after long-term use, such as psychiatric problems, dermatological reactions, increase in body weight, lower sex-drive, nausea, headache, upset stomach and weakness, thus not significantly outweighing the benefit of premature ejaculation medication versus the risks. By contrast with SSRIs approved for depression, which take 2 weeks or longer to reach steady-state concentration, dapoxetine has a unique pharmacokinetic profile, with a short time to maximum serum concentration (about 1 h) and rapid elimination (initial half-life of 1-2 h).
Mechanism of actionThe drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation.
Related Articles
AbsorptionRapidly absorbed.
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeInitial half-life of 1-2 hours.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9933
Blood Brain Barrier+0.9758
Caco-2 permeable+0.817
P-glycoprotein substrateSubstrate0.5085
P-glycoprotein inhibitor IInhibitor0.6464
P-glycoprotein inhibitor IINon-inhibitor0.8833
Renal organic cation transporterInhibitor0.74
CYP450 2C9 substrateNon-substrate0.7484
CYP450 2D6 substrateSubstrate0.7615
CYP450 3A4 substrateSubstrate0.7727
CYP450 1A2 substrateInhibitor0.9354
CYP450 2C9 inhibitorNon-inhibitor0.7353
CYP450 2D6 inhibitorNon-inhibitor0.5597
CYP450 2C19 inhibitorNon-inhibitor0.7689
CYP450 3A4 inhibitorNon-inhibitor0.8382
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6419
Ames testAMES toxic0.6626
CarcinogenicityNon-carcinogens0.8718
BiodegradationNot ready biodegradable0.9866
Rat acute toxicity2.5199 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.6032
hERG inhibition (predictor II)Inhibitor0.663
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage formsNot Available
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000837 mg/mLALOGPS
logP4.75ALOGPS
logP4.67ChemAxon
logS-5.6ALOGPS
pKa (Strongest Basic)9.04ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area12.47 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity96.14 m3·mol-1ChemAxon
Polarizability35 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis ReferenceNot Available
General References
  1. Safarinejad MR: Safety and efficacy of dapoxetine in the treatment of premature ejaculation: a double-blind, placebo-controlled, fixed-dose, randomized study. Neuropsychopharmacology. 2008 May;33(6):1259-65. Epub 2007 Jul 11. [PubMed:17625501 ]
  2. Cirillo-Penn K, Modi NB: Dapoxetine and paroxetine for the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):315. [PubMed:17909314 ]
  3. McMahon C: Dapoxetine in the treatment of premature ejaculation. Clin Neuropharmacol. 2007 Sep-Oct;30(5):314-5. [PubMed:17909313 ]
  4. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. [PubMed:17624269 ]
  5. Pryor JL, Althof SE, Steidle C, Rosen RC, Hellstrom WJ, Shabsigh R, Miloslavsky M, Kell S: Efficacy and tolerability of dapoxetine in treatment of premature ejaculation: an integrated analysis of two double-blind, randomised controlled trials. Lancet. 2006 Sep 9;368(9539):929-37. [PubMed:16962882 ]
  6. Hellstrom WJ, Heintz JW: Treatment of premature ejaculation: new drugs and treatment strategies. Curr Urol Rep. 2006 Nov;7(6):473-8. [PubMed:17052444 ]
  7. Modi NB, Dresser M, Desai D, Edgar C, Wesnes K: Dapoxetine has no pharmacokinetic or cognitive interactions with ethanol in healthy male volunteers. J Clin Pharmacol. 2007 Mar;47(3):315-22. [PubMed:17322143 ]
  8. Payne RE, Sadovsky R: Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007 May;74 Suppl 3:S47-53. [PubMed:17546831 ]
External Links
ATC CodesG04BX14
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
AlfuzosinDapoxetine may increase the orthostatic hypotensive activities of Alfuzosin.
AlmotriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Almotriptan.
AmitriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amitriptyline.
AmlodipineDapoxetine may increase the orthostatic hypotensive activities of Amlodipine.
AmoxapineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Amoxapine.
AprepitantThe serum concentration of Dapoxetine can be increased when it is combined with Aprepitant.
AtazanavirThe serum concentration of Dapoxetine can be increased when it is combined with Atazanavir.
AvanafilDapoxetine may increase the orthostatic hypotensive activities of Avanafil.
Azilsartan medoxomilDapoxetine may increase the orthostatic hypotensive activities of Azilsartan medoxomil.
BenazeprilDapoxetine may increase the orthostatic hypotensive activities of Benazepril.
BoceprevirThe serum concentration of Dapoxetine can be increased when it is combined with Boceprevir.
BromocriptineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Bromocriptine.
BuspironeThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Buspirone.
CabergolineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cabergoline.
CandesartanDapoxetine may increase the orthostatic hypotensive activities of Candesartan.
CaptoprilDapoxetine may increase the orthostatic hypotensive activities of Captopril.
CeritinibThe serum concentration of Dapoxetine can be increased when it is combined with Ceritinib.
CilazaprilDapoxetine may increase the orthostatic hypotensive activities of Cilazapril.
CitalopramThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Citalopram.
ClarithromycinThe serum concentration of Dapoxetine can be increased when it is combined with Clarithromycin.
ClevidipineDapoxetine may increase the orthostatic hypotensive activities of Clevidipine.
ClomipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Clomipramine.
CobicistatThe serum concentration of Dapoxetine can be increased when it is combined with Cobicistat.
CrizotinibThe serum concentration of Dapoxetine can be increased when it is combined with Crizotinib.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Cyclobenzaprine.
DarunavirThe serum concentration of Dapoxetine can be increased when it is combined with Darunavir.
DelavirdineThe serum concentration of Dapoxetine can be increased when it is combined with Delavirdine.
DesvenlafaxineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Desvenlafaxine.
DextromethorphanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dextromethorphan.
DihydroergotamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Dihydroergotamine.
DiltiazemThe serum concentration of Dapoxetine can be increased when it is combined with Diltiazem.
DoxazosinDapoxetine may increase the orthostatic hypotensive activities of Doxazosin.
DoxepinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Doxepin.
DronedaroneThe serum concentration of Dapoxetine can be increased when it is combined with Dronedarone.
DuloxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Duloxetine.
EletriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Eletriptan.
EnalaprilDapoxetine may increase the orthostatic hypotensive activities of Enalapril.
EnalaprilatDapoxetine may increase the orthostatic hypotensive activities of Enalaprilat.
EprosartanDapoxetine may increase the orthostatic hypotensive activities of Eprosartan.
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergoloid mesylate.
ErgonovineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergonovine.
ErgotamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Ergotamine.
ErythromycinThe serum concentration of Dapoxetine can be increased when it is combined with Erythromycin.
EscitalopramThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Escitalopram.
FelodipineDapoxetine may increase the orthostatic hypotensive activities of Felodipine.
FentanylThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fentanyl.
FluconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Fluconazole.
FluoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluoxetine.
FluvoxamineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Fluvoxamine.
FosamprenavirThe serum concentration of Dapoxetine can be increased when it is combined with Fosamprenavir.
FosinoprilDapoxetine may increase the orthostatic hypotensive activities of Fosinopril.
FrovatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Frovatriptan.
HydralazineDapoxetine may increase the orthostatic hypotensive activities of Hydralazine.
IdelalisibThe serum concentration of Dapoxetine can be increased when it is combined with Idelalisib.
ImatinibThe serum concentration of Dapoxetine can be increased when it is combined with Imatinib.
ImipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Imipramine.
IndinavirThe serum concentration of Dapoxetine can be increased when it is combined with Indinavir.
IrbesartanDapoxetine may increase the orthostatic hypotensive activities of Irbesartan.
IsavuconazoniumThe serum concentration of Dapoxetine can be increased when it is combined with Isavuconazonium.
IsocarboxazidThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Isocarboxazid.
IsosorbideDapoxetine may increase the orthostatic hypotensive activities of Isosorbide.
Isosorbide DinitrateDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Dinitrate.
Isosorbide MononitrateDapoxetine may increase the orthostatic hypotensive activities of Isosorbide Mononitrate.
IsradipineDapoxetine may increase the orthostatic hypotensive activities of Isradipine.
ItraconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Itraconazole.
KetoconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Ketoconazole.
LevomilnacipranThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Levomilnacipran.
LinezolidThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Linezolid.
LisinoprilDapoxetine may increase the orthostatic hypotensive activities of Lisinopril.
LithiumThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lithium.
LorcaserinThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Lorcaserin.
LosartanDapoxetine may increase the orthostatic hypotensive activities of Losartan.
MaprotilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Maprotiline.
MethadoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Methadone.
MifepristoneThe serum concentration of Dapoxetine can be increased when it is combined with Mifepristone.
MilnacipranThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Milnacipran.
MinoxidilDapoxetine may increase the orthostatic hypotensive activities of Minoxidil.
MirtazapineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Mirtazapine.
MoclobemideThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Moclobemide.
MoexiprilDapoxetine may increase the orthostatic hypotensive activities of Moexipril.
NaratriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Naratriptan.
NefazodoneThe serum concentration of Dapoxetine can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir.
NicardipineDapoxetine may increase the orthostatic hypotensive activities of Nicardipine.
NifedipineDapoxetine may increase the orthostatic hypotensive activities of Nifedipine.
NilotinibThe serum concentration of Dapoxetine can be increased when it is combined with Nilotinib.
NimodipineDapoxetine may increase the orthostatic hypotensive activities of Nimodipine.
NisoldipineDapoxetine may increase the orthostatic hypotensive activities of Nisoldipine.
NitroglycerinDapoxetine may increase the orthostatic hypotensive activities of Nitroglycerin.
NortriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Nortriptyline.
OlmesartanDapoxetine may increase the orthostatic hypotensive activities of Olmesartan.
ParoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Paroxetine.
PerindoprilDapoxetine may increase the orthostatic hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Pethidine.
PhenelzineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Phenelzine.
PhenoxybenzamineDapoxetine may increase the orthostatic hypotensive activities of Phenoxybenzamine.
PhentolamineDapoxetine may increase the orthostatic hypotensive activities of Phentolamine.
PosaconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Posaconazole.
PrazosinDapoxetine may increase the orthostatic hypotensive activities of Prazosin.
ProcarbazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Procarbazine.
PromethazineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Promethazine.
ProtriptylineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Protriptyline.
QuinaprilDapoxetine may increase the orthostatic hypotensive activities of Quinapril.
RamiprilDapoxetine may increase the orthostatic hypotensive activities of Ramipril.
RasagilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rasagiline.
RitonavirThe serum concentration of Dapoxetine can be increased when it is combined with Ritonavir.
RizatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Rizatriptan.
SaquinavirThe serum concentration of Dapoxetine can be increased when it is combined with Saquinavir.
SelegilineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Selegiline.
SertralineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sertraline.
SildenafilDapoxetine may increase the orthostatic hypotensive activities of Sildenafil.
SilodosinDapoxetine may increase the orthostatic hypotensive activities of Silodosin.
SumatriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Sumatriptan.
TadalafilDapoxetine may increase the orthostatic hypotensive activities of Tadalafil.
TamsulosinDapoxetine may increase the orthostatic hypotensive activities of Tamsulosin.
TapentadolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tapentadol.
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tedizolid Phosphate.
TelaprevirThe serum concentration of Dapoxetine can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Dapoxetine can be increased when it is combined with Telithromycin.
TelmisartanDapoxetine may increase the orthostatic hypotensive activities of Telmisartan.
TerazosinDapoxetine may increase the orthostatic hypotensive activities of Terazosin.
ThioridazineDapoxetine may increase the arrhythmogenic activities of Thioridazine.
TramadolThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tramadol.
TrandolaprilDapoxetine may increase the orthostatic hypotensive activities of Trandolapril.
TranylcypromineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Tranylcypromine.
TrazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trazodone.
TrimipramineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Trimipramine.
ValsartanDapoxetine may increase the orthostatic hypotensive activities of Valsartan.
VardenafilDapoxetine may increase the orthostatic hypotensive activities of Vardenafil.
VenlafaxineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Venlafaxine.
VerapamilThe serum concentration of Dapoxetine can be increased when it is combined with Verapamil.
VilazodoneThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vilazodone.
VoriconazoleThe serum concentration of Dapoxetine can be increased when it is combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vortioxetine.
ZolmitriptanThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Zolmitriptan.
Food InteractionsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Molecular Weight:
46106.335 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Molecular Weight:
43567.535 Da
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Wang WF, Chang L, Minhas S, Ralph DJ: Selective serotonin reuptake inhibitors in the treatment of premature ejaculation. Chin Med J (Engl). 2007 Jun 5;120(11):1000-6. [PubMed:17624269 ]
Comments
comments powered by Disqus
Drug created on October 21, 2007 05:51 / Updated on August 17, 2016 12:24